Related Experiment Video
Updated: Jan 8, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Vaccine Therapy, Oncolytic Viruses, and Gliomas
Abstract:
After years of active research and refinement, vaccine therapy and oncolytic viruses are becoming part of the arsenal in the treatment of gliomas. In contrast to standard treatment with radiation therapy and chemotherapy, vaccines are more specific to the patient and the tumor. The majority of ongoing vaccine trials are investigating peptide, heat shock protein, and dendritic cell vaccines. The immunosuppression triggered by the tumor itself and by its treatment is a major obstacle to vaccine and oncolytic virus therapy. Thus, combination therapy with different agents that affect the immune system will probably be necessary.
Insights
Vaccine therapy and oncolytic viruses offer targeted glioma treatment, but tumor-induced immunosuppression necessitates combination therapies for efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Virology
Background:
- Gliomas are challenging brain tumors with limited treatment options.
- Standard therapies like radiation and chemotherapy have significant side effects.
- Emerging treatments include vaccine therapy and oncolytic viruses, offering tumor-specific approaches.
Purpose of the Study:
- To review the current state and challenges of vaccine and oncolytic virus therapies for gliomas.
- To highlight the potential of these novel immunotherapies in cancer treatment.
Main Methods:
- Review of current research and clinical trials on glioma vaccines (peptide, heat shock protein, dendritic cell) and oncolytic viruses.
- Analysis of the role of tumor-induced immunosuppression as a therapeutic barrier.
Main Results:
- Vaccine and oncolytic virus therapies are advancing as specific treatment modalities for gliomas.
- Tumor microenvironment and treatment-related immunosuppression significantly impede the effectiveness of these immunotherapies.
- Ongoing trials focus on various vaccine types, including peptide, heat shock protein, and dendritic cell vaccines.
Conclusions:
- Vaccine and oncolytic virus therapies show promise for glioma treatment due to their specificity.
- Overcoming immunosuppression is critical for the success of these novel therapies.
- Combination strategies involving agents that modulate the immune system are likely essential for future treatment protocols.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...